Los Angeles Capital Management LLC Invests $153,000 in Perspective Therapeutics, Inc. (NYSE:CATX)

Los Angeles Capital Management LLC acquired a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 11,424 shares of the company’s stock, valued at approximately $153,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CATX. Sykon Capital LLC increased its holdings in shares of Perspective Therapeutics by 4.7% in the second quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock worth $378,000 after purchasing an additional 1,717 shares during the last quarter. US Bancorp DE boosted its stake in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after buying an additional 3,866 shares during the period. nVerses Capital LLC bought a new position in Perspective Therapeutics during the third quarter valued at $57,000. Victory Capital Management Inc. bought a new position in Perspective Therapeutics during the 2nd quarter valued at about $117,000. Finally, Point72 DIFC Ltd bought a new position in shares of Perspective Therapeutics during the second quarter valued at approximately $118,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Truist Financial started coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of Perspective Therapeutics in a research report on Thursday, October 24th. Bank of America initiated coverage on Perspective Therapeutics in a report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective for the company. Finally, UBS Group began coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Buy” and an average target price of $21.57.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $6.95 on Tuesday. Perspective Therapeutics, Inc. has a 12-month low of $2.28 and a 12-month high of $19.05. The business’s fifty day simple moving average is $12.55.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, analysts predict that Perspective Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.